固本抑瘤Ⅱ号对人A_（549）肺癌细胞、小鼠Lewis肺癌作用的实验研究
|
摘要
肺癌是最常见的恶性肿瘤之一,在我国大城市中肺癌的发病率和死亡率居肿瘤之首,在农村居第4位,严重威胁着人类健康,肺癌的治疗研究成为肿瘤研究的焦点之一。由于西药放、化疗毒副作用大,作用范围局限,使得中医药在肺癌治疗中的优势表现得越来越明显。中医认为肺癌主要是由于脏腑虚损、血瘀痰凝毒结而成。癌症病人,尤其是中晚期癌症患者普遍存在血瘀证或气虚血瘀证,应对证采用益气活血法治疗。益气活血法属于“扶正祛邪”范畴,具有益气不留寇,驱邪不伤正的功效。
固本抑瘤II号是北京市中医医院治疗气虚血瘀证肿瘤患者的有效方剂,常配合化疗应用。临床资料表明该方能够改善患者生活质量,减轻化疗的毒副作用。为探讨该方药抑瘤的有效成分及作用机制,本实验选用人肺腺癌细胞株A549,通过全方及拆方研究,观察该方及方中不同组分中药对A549细胞生长的影响,寻找固本抑瘤Ⅱ号方中抑瘤及化疗增效作用的主要成分。选用小鼠Lewis肺癌模型,观察该方及与化疗药物CTX合用对移植瘤、转移瘤的作用,以及固本抑瘤Ⅱ号方对小鼠免疫功能、荷瘤生存时间及细胞凋亡的影响,探讨该方的作用机制,指导临床合理用药。
1.固本抑瘤II号及其拆方对A549抑瘤作用及与化疗联合用药的实验研究
固本抑瘤II号全方和根据功效拆分的益气组、行气活血组、培补肝肾组、散结消癥组药物,分别制备水提物。采用MTT法检测各组药物对A549细胞生长的影响及与DDP联合作用的效果,FCM检测细胞周期和凋亡。结果显示:单独应用全方和行气活血组水提物对A549细胞生长表现为抑制作用,IC50分别为33.21mg生药/ml和9.55mg生药/ml;与DDP合用表现为增效作用,增效倍数分别为1.23和1.77,合并指数为1.05和0.83,表现出协同和相加作用;全方和行气活血组水提物能够使A549细胞生长阻滞在G0/G1期,百分比为84.16%和86.21%,减少进入S期的细胞数量。
2.固本抑瘤II号方对Lewis肺癌抑制作用及与化疗药联合应用的实验研究
60只体重19±1g雄性C57BL/6小鼠随机分对照组(Control)、CTX化疗组(CTX)(30mg/Kg CTX腹腔注射)、固本抑瘤II号小剂量组(M)(35g/Kg·d灌胃)、大剂量组(H)(70g/Kg·d灌胃)、小剂量加CTX组(M+CTX)、大剂量加CTX组(H+CTX),每组10只。观察固本抑瘤II号对Lewis肺癌移植瘤与转移瘤的作用,及与CTX合用的效果。结果显示:固本抑瘤II号M组、H组的抑瘤率(IR)分别为23.35%、36.82%,瘤重分别为2.82±1.56g、2.32±1.06g,与对照组3.68±1.10g相比明显缩小,分别p<0.05;M+CTX、H+CTX组抑瘤率分别为71.49%、67.13%,与CTX组的63.35%抑瘤率相比未表现出明显差异;但联合用药效应为0.85Lung cancer is the most common malignant tumor, morbidity and the mortality from which takes the first place in major cities in China, and the fourth in countrysides, obviously, it is threatening human’s health. The treatment study on lung cancer becomes the focus among the studies of tumor. Strong side effects of actinotheraphy and chemotherapeutics have their application limited. Instead, Traditional Chinese medicine has showing superiority in treatment on lung cancers. In Chinese medicine, lung cancer is a result of stagnation of blood and phlegm due to deficiency of Zang-fu organs. In fact, lung cancer sufferers, especially in late stage, did generally have symptomes with blood stagnation/or blood stagnation in Qi deficiency condition, so the treatment should be to strengthen qi---protecting body, and activate blood---eliminating pathogenic factors, by these two ways, a new balance will be built up again.
Gubenyiliu formula II(GII), produced by Beijing City Hospital of Traditional Chinese Medicine, is an effective prescription in treating cancer with syndrome of blood stasis and Qi deficiency, which is generally applied in combination with chemotherapeutics. Clinic datas proved that GII can improve the quality of life and lessen the side effects of chemotherapeutics. In order to study the effective functional ingredients and their acting mechanisms, our experiments individually detected the effects of whole prescription and its functional compositions to the growth of A549 adenocarcinoma cell, aiming at seeking out the specific active ingredient on inhibiting tumor or increasing the effects of chemotherapeutics, and hopefully could guide rational administration in clinic. We also observed the influence of GII(or with CTX) on transplantation tumor and metastatic tumor of mice’Lewis lung cancer, and the effection on immune system, living time and apopotosis.
1. In Vitro studies of GII and its functional compositions on A549 lung carcinoma cell and synergistic action in combination with chemotherapy
According to the actions of each herbs, GII was divided into four groups: Reforcing Qi group(QE)、Promoting qi and activating blood group(QB)、Cultivating kidney and liver group(KL)and Eliminating stagnation and removing lump group(SL). Their aqueous extracts were prepared respectively. MTT assay was used for A549 growth and combinative effect with DDP. Results: Both GII and QB group showed depressive effect on A549 growth. The IC50 was 33.21mg crude drug/ml and 9.55mg crude drug/ml respectively. Both of them had synergistic action with DDP, the multiple was 1.23 and 1.77, complicating index was 1.05 and 0.83. Both of them could obviously inhibit A549 cell growth in G0/G1 phase,the percentages were 84.16% and 86.21%respectively, and reduce the numbers of S phase.
固本抑瘤II号是北京市中医医院治疗气虚血瘀证肿瘤患者的有效方剂,常配合化疗应用。临床资料表明该方能够改善患者生活质量,减轻化疗的毒副作用。为探讨该方药抑瘤的有效成分及作用机制,本实验选用人肺腺癌细胞株A549,通过全方及拆方研究,观察该方及方中不同组分中药对A549细胞生长的影响,寻找固本抑瘤Ⅱ号方中抑瘤及化疗增效作用的主要成分。选用小鼠Lewis肺癌模型,观察该方及与化疗药物CTX合用对移植瘤、转移瘤的作用,以及固本抑瘤Ⅱ号方对小鼠免疫功能、荷瘤生存时间及细胞凋亡的影响,探讨该方的作用机制,指导临床合理用药。
1.固本抑瘤II号及其拆方对A549抑瘤作用及与化疗联合用药的实验研究
固本抑瘤II号全方和根据功效拆分的益气组、行气活血组、培补肝肾组、散结消癥组药物,分别制备水提物。采用MTT法检测各组药物对A549细胞生长的影响及与DDP联合作用的效果,FCM检测细胞周期和凋亡。结果显示:单独应用全方和行气活血组水提物对A549细胞生长表现为抑制作用,IC50分别为33.21mg生药/ml和9.55mg生药/ml;与DDP合用表现为增效作用,增效倍数分别为1.23和1.77,合并指数为1.05和0.83,表现出协同和相加作用;全方和行气活血组水提物能够使A549细胞生长阻滞在G0/G1期,百分比为84.16%和86.21%,减少进入S期的细胞数量。
2.固本抑瘤II号方对Lewis肺癌抑制作用及与化疗药联合应用的实验研究
60只体重19±1g雄性C57BL/6小鼠随机分对照组(Control)、CTX化疗组(CTX)(30mg/Kg CTX腹腔注射)、固本抑瘤II号小剂量组(M)(35g/Kg·d灌胃)、大剂量组(H)(70g/Kg·d灌胃)、小剂量加CTX组(M+CTX)、大剂量加CTX组(H+CTX),每组10只。观察固本抑瘤II号对Lewis肺癌移植瘤与转移瘤的作用,及与CTX合用的效果。结果显示:固本抑瘤II号M组、H组的抑瘤率(IR)分别为23.35%、36.82%,瘤重分别为2.82±1.56g、2.32±1.06g,与对照组3.68±1.10g相比明显缩小,分别p<0.05;M+CTX、H+CTX组抑瘤率分别为71.49%、67.13%,与CTX组的63.35%抑瘤率相比未表现出明显差异;但联合用药效应为0.85
Gubenyiliu formula II(GII), produced by Beijing City Hospital of Traditional Chinese Medicine, is an effective prescription in treating cancer with syndrome of blood stasis and Qi deficiency, which is generally applied in combination with chemotherapeutics. Clinic datas proved that GII can improve the quality of life and lessen the side effects of chemotherapeutics. In order to study the effective functional ingredients and their acting mechanisms, our experiments individually detected the effects of whole prescription and its functional compositions to the growth of A549 adenocarcinoma cell, aiming at seeking out the specific active ingredient on inhibiting tumor or increasing the effects of chemotherapeutics, and hopefully could guide rational administration in clinic. We also observed the influence of GII(or with CTX) on transplantation tumor and metastatic tumor of mice’Lewis lung cancer, and the effection on immune system, living time and apopotosis.
1. In Vitro studies of GII and its functional compositions on A549 lung carcinoma cell and synergistic action in combination with chemotherapy
According to the actions of each herbs, GII was divided into four groups: Reforcing Qi group(QE)、Promoting qi and activating blood group(QB)、Cultivating kidney and liver group(KL)and Eliminating stagnation and removing lump group(SL). Their aqueous extracts were prepared respectively. MTT assay was used for A549 growth and combinative effect with DDP. Results: Both GII and QB group showed depressive effect on A549 growth. The IC50 was 33.21mg crude drug/ml and 9.55mg crude drug/ml respectively. Both of them had synergistic action with DDP, the multiple was 1.23 and 1.77, complicating index was 1.05 and 0.83. Both of them could obviously inhibit A549 cell growth in G0/G1 phase,the percentages were 84.16% and 86.21%respectively, and reduce the numbers of S phase.
引文
1. 彭再梅,杨竹林,陈平,等.肺癌 PTEN 和 DPC4 基因的表达及其临床生物学意义.中华结核和呼吸杂志,2002,25(6):375-376
2. 王英年,崔言刚,张春玲,等.P15 蛋白、血管内皮生长因子在肺癌组织中的表达及相关性研究.中华结核和呼吸杂志,2001,24(2):115
3. 王孝养,陈仕新,张珍祥,等.Survivin 基因在非小细胞肺癌中的表达及与P53、c-myc、k-ras 蛋白表达的关系.中华结核和呼吸杂志,2001,24(6):371-374
4. Vejda S, Posovszky C.Plasma from cancer patients festuring a charactristic protein composions mediates protein against apoptosis [J].Mol cell Proteomics. 2002, 1(5): 387-393
5. Zhan XQ, Guan YJ. Differential proteomic analysis of human lungadenocacinoma cell line A549 and normal cell line HEB[J].Sheng wu hua xue yu sheng wu wu li xue bao (shanghai), 2002, 34(1): 50-56
6. 危北海.循证医学与中医药学发展.中医药学信息,2003,20(5):123
7. Mattson KV, Abratt RP, Velde G. Doeetaxel as neoadjuvant therapy for radically treatable stage Ⅲ non-small-cell lung cancer: amμltinational radomised phase Ⅲ study. Acta Oncol, 2003, 14: 116-122
8. Garrido Lopez MP, Lago J, Gonzalez-Larriba L, et al. Neodjuvant chemotherapy with Gemcitabine (GEM), cisplath (CIS) and Docetaxel (DOC) in stage ⅢA N2 and T4N0 non-small-cell lung cancer (NSCLC) patients: spanish lung cancer group phase Ⅱ trial 9901. Proc Am Soc Clin Oncol, 2003, 22: 2620.
9. Antomio S, Rebecca P, Alberto T, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage ⅢA N2/ ⅢB nonsmall cell lung cancer (NSCLC): a mμlticenter phase Ⅱstudy with a 21 days schedμle: final resμlts. Proc Am Soc Clin Oncol, 2003, 22: 2669.
10.The international adjuvant lung cancer trial collaborative group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell-lung-cancer. New Engl J Med, 2004, 350(4): 351.
11.Winton T , Livingston R , Johnson D ,et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin ( CIS) in completely resected staged ⅠB and Ⅱ non-small cell lung cancer (NSCLC) interground JBR 10. Proc Am Soc Clin Oncol, 2004 , 23 (Suppl) : 7018a
12.吴一龙.非小细胞肺癌综合治疗的再认识.循证医学,2004,4(4):193-195
13.申文江,徐国镇,主编.放射肿瘤学新进展.北京:中国医药科技出版社,2001,289
14.王远东,赵健,刘健雄,等.射频治疗在局部晚期非小细胞肺癌综合治疗中的作用.中国肿瘤临床,2004,31(9):499-501
15.Raben D, Helf rich BA, Chan D, et al. ZD1839, as selective epidermal growth factor receptor tyrosine kinase inhibitor alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminn Oncol, 2002, 29 (s4): 37-46
16.Tsai CM, Chang KT, Wu L H, et al. Correlation between intrinsic chemoresistance and HER-2/ neμgene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res, 1996, 56: 206-209
17.Fukuoka M, Kris M, Giaccone G, et al. Phase Ⅱt rails of gefitinib (Iressa, ZD1839): rapid and durable objective responses in patients with advancednon-small-cell lung cancer (IDEAL1 and IDEAL2). Lung Cancer, 2003, 41 (Suppl 2): S247
18.Herbst RS. Dose-comparative monot herapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30 (1Suppl 1): 30-38
19.王树森,管忠霞,姜文奇,等.表皮生长因子受体酪氨酸激酶抑制剂 ZD1839对鼻咽癌细胞系的作用.癌症,2004,23(5):540-544
20.Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer togefitinib. New Engl J Med, 2004, 350(21): 2129-2139
21.Sandier AB. Clinical experience with tarceva. Lung Cancer. 2003, 41 (s3): s82
22.Miller VA, PatelJ, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patints with bronchioloaveolar cell carcinoma (BAC): preliminary resμlts of a phase II trial. Proc Am Soc Clin Oncol, 2003, 22: 619
23.Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 2004, 6 (Suppl 1): S24-29
24.Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. New Engl J Med, 2004, 351 (4): 337-345
25.Kim ES. Cetuximab as a single agent or in combination with chemotherapy in lung cancer. Clin Lung Cancer, 2004, 6 (Suppl2): S80-84
26.Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2004, 23:618. Abs 7012
27.Mcarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascμlar endot helial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther, 2004, 3 (9): 1041-1048
28.Heymach JV, Dong RP, Dimery I, et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Resμlts of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol, 2004, 23: 207s, Abs 3051
29.Sandler AB, Gray R, Brahmer J, et al. A randomized phase III trial comparing bevacizumab/ carboplatin/ paclitaxel versus carboplatin/ paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2005, 23: 621s. Abs 7001
30.Wojtowicz-Praga SM, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol, 1998, 16: 2150-2156
31.Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastatafter response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol, 2002, 20: 4434- 4439
32.Rigas J R, Denham CA, Rinaldi D, et al. Adjuvant targeted therapy in unresectable lung cancer: The resμlts of two randomized placebo-controlled trials of BAY 12-9566, a Matrix Metalloproteinase Inhibitor (MMPI). Lung Cancer, 2003, 41(s2): s34
33.Gridelli C. How to combine cytotoxic and cytostatic agents. Lung Cancer, 2002, 38: s39-40
34.Nμgent FW, Graziano S, Collea R, et al. Docetaxel and COX-2 inhibitoion with celecoxib in progressive non-small cell lung cancer (NSCLC): promising progression-free survival in a Phase II study. Lung Cancer, 2003, 41 (s2): s35-s36
35.梅玫,余虹,张维铭,等.硫代修饰型反义寡核苷酸酶抑制肺癌细胞系端粒酶活性及增殖的研究.中华病理杂志,2000,29:204-207
36.Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a Bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol, 2002, 13 (4): 539-545
37.Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst, 2001, 93(6): 463-471
38.Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53 resistant cancer lines. Cancer Res, 2000, 60 (5): 1157-1161
39.Jin Z, Dicker DT, Ei-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells sμggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 2002, 1 (1): 82-89
40.Huang X, Lin T, Gu J, et al. Combined TRAIL and Bax gene therapy prolongedsurvival in mice with ovarian cancer xenograft. Gene Ther, 2002, 9(20): 1379-1386
41.Ianniello GP, De Cataldis G, Comella P, et al. Visplatin, epirubicin and vindesine with or without lonidamine in the treatment of inoperable non-small cell lung carcinoma: a mμlticenter randomized trial. Cancer, 1996, 78 (1): 63-69
42.Paμl A, Bunn Jr MD, Ariel SMD, et al. New therapeutic strategies for lung cancer-biology and molecμlar biology come of age. Chest, 2000, 117 (4 Suppl 1): 163S-168S
43.Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer throμgh endobronchial injection. Chest, 2000, 118(4): 966-970
44.Schμler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: resμlts of a mμlticenter phase II study. J Clin Oncol, 2001, 19 (6): 1750-1758
45.Yuen A, Halsey J, Fisher GA ,et al. Phae I/ II trial of ISIS3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 309. Abs 1234
46.Lynch TJ, Rayu R, Lind M, et al. Randomized phase Ⅲ trial of Ly90003 (ISIS3521) in patients with advanced NSCLC inital report. Proc Am Soc Clin Oncol, 2003, 22: 623. Abs2504
47.Boehm T , Folkmam J ,Browder T ,et al . Antiangiogenic therapy of experimental cancer does not induce acquired drμg resistance. Nature, 1997, 390 (6658): 404-407
48.Gatzemeier U, Rodriguez G, Treat J, et al. Triapazamine-cisplatin: the synergy. Br J Cancer, 1998, 77(Suppl 4): 415-417
49.Macaμlay VM ,O′Byrne KJ ,Saumders MP ,et al . Phase I study of int ropleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effeusions. Clin Cancer Res, 1999, 5 (3): 513-520
50.Liao F, Li Y, O’Connor W, et al. Monoclonal antibody to vascμlar endot helial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res, 2000, 60(24): 6805-6810
51.Zang Y, Griffith EC, Sage J, et al. Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21 WAPF1/ CIP1. Proc Natl Acad Sci USA, 2000, 97 (12): 6427-6432
52.Hagedorm M, Bikfalvi A. Target molecμles for anti-angiogenic therapy: frombasic research to clinicle trials. Crit Rev Oncol Hematol, 2000, 34 (2): 89-110
53.Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med, 2000, 108 (6): 487-495
54.Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascμlar endot helial growth factor receptor into a remote organ. Cancer Res, 2000, 60 (8): 2169-2177
55.Li H, Lu H, Griscelli F, et al . Adenovirus-mediated delivery of a uPA/ uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther, 1998, 5(8): 1105-1113
56.Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg, 2002, 235 (4): 540-549
57.Zhou Y, McEarchern JA. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunol Immunother, 2003, 52 (7): 413-422
58.Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunot herapy of cancer with carcinoembryonic antigen-derived, HLA-A24-rest ricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinoma. Int J Oncol, 2004, 24 (4): 909- 917
59.Butts C. A mμlticenter phase IIB randomized study of the liposomal muc1 vaccine L-BLP25 for immunot herapy of advanced non-small cell lung cancer (NSCLC). Proceedings from the 11th world conference on lung cancer, Barcelona, Spain, 2005, Abs O-083
60.Nemunaitis J, Sterman D. Granμlocyte-macrophage colony-stimμlating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst, 2004, 96 (4): 326- 331
61.Spira A, Ettinger DS. Mμltidisciplinary management of lung cancer. N Engl J Med, 2004, 350 (4): 379-392
62.Langer CJ. Role of targeted therapy in non-small cell lung cancer: hype or hope? Expert Rev Anticancer Ther, 2003, 3 (4): 443-455
63.朱熊兆.心理干预对人体免疫调节功能的影响.中国临床康复,2002,6(17):2520-2522
1. 王国智.肿瘤临床辨治体会.陕西中医,1997,18(4):191
2. 王云启.肺复方治疗非小细胶肺癌 30 例临床观察.湖南中医杂志,2000,16(3):9
3. 朱惠蓉.益肺抗癌饮治疗晚期肺癌 28 例临床观察.湖南中医杂志,2000,16(3):8
4. 魏华.晚期肺癌的中医药治疗.湖北中医杂志,2000,22(8):20
5. 王家辉.中药配合放化疗治疗晚期非小细胞肺癌 36 例.中国中西医结合杂志,1998,18(9):562
6. 孙维刚.孙宜麟治疗癌症临证举隅.辽宁中医杂志,1998,25(6):264
7. 张齐军.补肺汤在肺癌虚证中的应用.湖北中医杂志,1999,21(5):225
8. 韩新平.抗癌协定方加辨证用药治疗晚期肺癌 17 例观察.河北中医药学报,1999,14(2):13
9. 海青,李世业,付瑜,等.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,1999,26(6):477-478
10.潘子民,人参皂甙 Rg3 对荷卵巢癌的严重免疫缺陷鼠的抗肿瘤血管生成作用的研究.中华妇科杂志,2002,37(4):227-230
11.计磊,陈士壮,李西启,等.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药,1997,(11):30-31
12.陈孝银,沈卓群.琼玉膏对化疗实验肺癌小鼠 nm23 及 PCNA 基因蛋白表达的影响.安徽中医学院学报,2000,19(2):47-49
13.张青,郁仁存,丁瑞,等.固本抑瘤Ⅱ号对小鼠肺腺癌移植后抑瘤作用和术后存活率的实验研究.中国中医药信息杂志,1997,4(10):14-15
14.韩明权,刘嘉湘,高虹,等.24 味中药对人肺腺癌细胞核酸和蛋白质及细胞周期的影响观察.中国中西医结合杂志,1995,15(3):147-149
15.许玲.刘嘉湘教授辨治肺癌经验.中医药信息,1995,12(4):36
16.唐文秀,张宗歧,林红生,等.中医药治疗晚期原发性非小细胞肺癌的临床观察.中医杂志,1994,35(5):283
17.范忠泽,孙钰,袁秀英.中医药对晚期原发性肺腺癌的疗效观察.中国中西医结合杂志,1994,14(9):561
18.王笑民,郁仁存,王禹堂,等.晚期非小细胞肺癌患者气虚血瘀证的研究.中国中西医结合杂志,1994,14(12):724
19.周晓园.顾报东治疗肿瘤的经验.山东中医杂志,1999,21(5):225
20.王云启.肺复方治疗非小细胞肺癌 30 例临床观察.湖南中医杂志.2000,16(3):9
21.张齐军.补肺汤在肺癌虚证中的应用.湖北中医杂志,1999,21(5):225
22.王敬亭.中西医结合治疗晚期肺癌 14 例.中国中西医结合杂志.1997,17(1):56
23.王永林,苏旭春.扶正清肺方减轻肺癌化疗反应的临床研究.中药药理与临床,2000,16(5):45
24.韩建国,魏兰波.益气养阴汤治疗晚期非小细胞肺癌的临床观察.辽宁中医杂志,2003,30(2):123
25.黄兆明.中药加化疗治疗晚期非小细胞肺癌疗效分折.中国中西医结合杂志,1997,17(1):26
26.王笑民.益气活血散结法配合化疗治疗晚期非小细胞肺癌的研究.中国中西医结合杂志.1997,17(2):86
27.王晓.中西医结合治疗晚期非小细胞肺癌疗效观察.中国中西医结合杂志,1997,17(2):13
28.潘淑云,孙维刚,丁隽英.中药软坚散结汤治疗晚期非小细胞肺癌 30 例.辽宁中医杂志,2002,29(12):723
29.陈世伟.温阳益气汤治疗晚期肺癌 50 例临床观察.山东中医杂志,2002,20(10):589
30.刘加宽.六仙汤治疗晚期非小细胞性肺癌临床观察.中国中西医结合杂志,2001,21(1):57
31.付显成.益气活血方配合放疗及介入化疗治疗晚期非小细胞肺癌的临床研究[J].中国中西医结合外科杂志,2000,6(5):313
32.刘秀芳.中药配合同步放、化疗对晚期非小细胞肺癌影响.中国中西医结合杂志,2000,20(6):427
33.郭孝忠,宋翠力,张存悌.肺癌用药规律初探.辽宁中医杂志,2002,29(5):273
34.宣丽华,徐福,刘鲁明.温经膏穴位外敷治疗肺癌疗效观察.浙江中西医结合杂志,2000,10(10):596～597
35.田建辉,刘运霞,祝宝刚,等.抗癌腹水膏穴位贴敷对艾氏腹水癌小鼠外周血 sIL-2R 水平的影响.中国针灸,2001,21(9):559～561
36.杨葆康,姜仁成.灵仙丹治疗中晚期肺癌 16 例.辽宁中医杂志,1994,21(7):323
37.谢止中,刘丹,沈汉澄.孔最穴位注射止血敏治疗中、晚期肺癌出血 53 例.中国中西医结合杂志,1998,18(8):495
1. 全国肿瘤防治研究办公室,中国试点市、县恶性肿瘤的发病与死亡.中国医药科技出版社,2000:25-26,32-33
2. 张青,郁仁存,王笑民,等.固本抑瘤Ⅱ号结合化疗治疗肿瘤的临床研究.中医杂志,1999(增刊)
3. 张青,郁仁存,王笑民,等.固本抑瘤Ⅱ号抗肿瘤的临床研究.中国中医药信息杂志,2000,7(7):41-42
4. 谢冰芬,潘启超,刘宗潮,等.固本抑瘤 II 号方对抗癌药物的增效作用.癌症,1996,15(3):181-183
5. 张青,郁仁存,丁瑞,等.固本抑瘤 II 号对小鼠肺腺癌移植后抑瘤作用和术后存活率的实验研究.中国中医药信息杂志,1997,4(10):14-15
6. 田宏印.黄芪化学研究及其有效成分[J] .云南民族学院报(自然科学版),1996,45(1):75-76
7. 马占好,张春艳,刘旭,等.黄芪多糖对小鼠体内六种细胞系瘤株抑瘤作用的实验研究[J] .中医药学报,1996,(4): 551
8. 郭颖杰.黄芪水煎液对人黑色素瘤细胞的杀伤作用.中草药, 2001,(31):114
9. 王涌,胡志前,成志刚,等.中药黄芪对阻塞性黄疸大鼠细胞免疫功能的影响[J] .肝胆外科杂志,2000,8(1):64-66
10.张建新.黄芪对小鼠免疫功能影响的研究.时珍国医国药,2000,11(6)∶488
11.洪介民,邱健行,胡祖光.黄芪多糖在体外对小鼠粒巨噬系祖细胞的影响.中医药学报,1997,(6):441
12.李智军,魏连波,贺丰,等.黄芪多糖治疗大鼠系膜细胞增生性肾炎的实验研究.中国中西医结合肾病杂志,2000,1(4):206
13.焦柏忠,刘晓晶,吕美丽,等.肝脾康胶囊药理作用研究.中草药,1999,30 (12):926-929
14.马红.黄芪抑制大鼠肝星状细胞增殖及胶原分泌的研究.中国中医药信息杂志,2001,8(4):35
15.周钦.芪对肾小球疾病物质代谢紊乱的调节作用.中草药,1999,30(5):386
16.周吉燕.黄芪中不同提取成分对在体大鼠心肌缺血-再灌注损伤的心功能影响.中国中药杂志,2000,25(5):300
17.冯国清.黄芪对大鼠心肌缺血-再灌注损伤的防护作用.中药药理与临床,1997,13(3):27
18.梁明,韩竹梅,梁小光,等.黄芪冻干粉对大鼠离体心脏的作用.中草药,2000,31(11):846-847
19.石瑞如,何路明,胡雅儿,等.黄芪对老年大鼠脑 M 胆碱受体的调节作用.中医杂志,1998,(11):685
20.金若敏,张晓晨,陈长勋,等.黄芪毛状根药理作用的研究.中国中药杂志,1999,24(10):619-621
21.马占好,张春艳,刘旭,等.黄芪多糖对小鼠体内六种细胞系瘤株抑瘤作用的实验研究.中医药学报,1996,(4):55
22.洪庚辛.黄芪水提物的促智作用.中国中药杂志,1994,19(11):687
23..胡守友,陈龙帮,王靖华,等.β-榄香烯对小鼠黑色素瘤细胞的分化诱导作用.南京大学学报.自然科学版,1998,34(5):550-553
24.高宪琴,王永才,苗小艳,等.榄香烯抗白血病作用的临床观察.大连医科大学学报,1999,21(1):27-28
25.石灵春,吴万根,张维彬,等.莪术油对小鼠肝癌增殖细胞核抗原的影响.世界华人消化杂志,1999,7(2):156-157
26.杨骅,王仙平,郁琳琳,等.榄香烯抗癌作用与诱发肿瘤细胞凋亡.中华肿瘤杂志,1996,18(3):169
27.徐学军,周子成,罗元辉,等.β-榄香烯诱导人肝癌细胞株 SMMC-7721 凋亡的研究.第三军医大学学报,1999,21(4):268-270
28.吴万垠,罗云坚,程剑华,等.莪术油对小鼠肝癌细胞 DNA 作用的图像分析.中西医结合肝病杂志,1999,9(1):18
29.崔秀云,李德山.β-榄香烯对 RNA 聚合酶活性的抑制及与 DNA 的结合.中国药理学报,1991,7(3):228
30.李应东,李啸红,王毓美,等.莪术对硫酸镍诱导的人外周血淋巴细胞非程序脱氧核糖核酸合成的影响.中国中西医结合杂志,1994,14(11):647-650
31.陈剑群,吴克俭,费素娟.榄香烯乳注射液治疗中晚期消化系肿瘤前后 T 淋巴细胞亚群的动态观察.中国肿瘤临床,1996,23(4):299-301
32.齐永长,吴厚生,胡新美,等.β-榄香烯、丝裂霉素 C 及热休克对小鼠 H22肝癌细胞 HSP70 表达的影响.上海免疫学杂志,1998,18(5):280-282
33.卞长武,王东荣,郭文来,等.莪术对小白鼠免疫功能的影响.中国中医药信息杂志,1997,4(2):29
34.李振波,丘和明,刘国普,等.清毒饮和养正片对环磷酰胺所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1):34-37
35..薄芯,杜明莹,戌梅.沙参、砂仁、猪苓、莪术和鸡血藤对环磷酰胺毒副反应影响的实验研究.中国中医药科技,1997,4(3):153,154,175
36.茅国新,高志兰,翟明之.榄香烯治疗晚期非小细胞肺癌的研究.中国肿瘤临床,1996,23(1):73-75
37.毛春芹,谢辉,陆免林.莪术炮制品的抗血小板聚集及抗凝血作用.中药材,2003,23(7):212-213
38.申庆亮.莪红注射液对血液流变学影响.中草药,1992,23(6):305-307
39.陈梅芳,丁钰熊,王家冲,等.大白鼠 5/6 肾切除所致慢性肾衰动物模型的中药疗效观察.中国医药学报,1988,3(6):24-27
40.杜兰屏,胡仲仪,邓跃毅,等.莪术对肾脏细胞外基质影响的实验研究.上海中医药杂志,2002,6(1):38-39
41.李应东,李啸红,王毓变.中药莪术抗致突变作用的初步研究.中国优生与遗传杂志,1999,7(1):22-23
42.李莲姬,韩春姬,崔山田,等.莪术对老年小鼠学习记忆与脂质过氧化作用的影响.中药材,1998,21(10):522-523
43.王鑫,刘玉瑛,史天良,等.白术挥发油抗实体瘤的作用研究.中国药物与临床,2002,2(4):239
44.焦新生,刘朝奇,朝莉,等.黄芪和白术对感染的色念珠菌的荷瘤鼠作用的实验.上海免疫学杂志,1995,15(5):313
45.关晓辉,曲娴,杨志萍,等.白术挥发油对小鼠免疫功能的影响.北华大学学报(自然科学版),2001,2(2):122
46.周德文.术类的药理和药效.国外医药·植物药分册,1996,11(3):120-122
47.余上才,章育正,赵慧娟,等.枸杞子和白术免疫调节作用的实验研究.上海免疫学杂志,1994,14(1):12
48.吕圭源.白术抗衰老作用研究.现代应用药学,1996,13(5):26-29
49.马晓松,樊雪萍,陈忠.白术对离体豚鼠回肠收缩的影响.新消化病学杂志,1996,4(11):603
50..蒲含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用.中国药理学通报,2000,16(1):60
51.李继承,吕志莲,石光和.腹膜孔的药物调节和计算机图象处理.中国医学科学院学报,1996,18(3):219
52.陈道峰.中药鸡血藤的原植物调查与商品鉴定.中草药,1993,24(1):34
53.崔艳君,陈若芸.鸡血藤化学和药理研究进展.天然产物研究与开发,2002,14(4):72-78
54.李静.鸡血藤化学成分的研究Ⅱ.中国药学杂志,1999,34(10):686
55.Xiu Wei Yang et al. Anti-lipid peroxidative effect of an extract of the stems of Kadsura heteroclita and its major constituents, kadsurin, in mice. Chen. Ppharm. Bμll, 1992, 40(2): 406
56.程小芳,何明芳,张颖,等.女贞子化学成分的研究.中国药科大学学报,2000,31(3):170
57.孟静岩,片岗宽章,保岛一树,等.女贞子苋芪汤抗癌转移的离体实验研究.天津中医学院学报,2001,20(3):32-34
58.丁安伟,孟丽.女贞子多糖的免疫调节作用研究.中药药理与临床,2001,17 (2):11-12
59.王昊,闰小萍.通脉益智胶囊对 30 例血管性痴呆患者内皮素和降钙素基因相关肽的影响.北京中医药大学学报,2000,23(2):64-65
60.彭小英,李晴宇,侯芳,等.复方女贞子降血糖作用的实验研究.上海实验动物科学,2001,21(2):103-104
61.范卫星,朱文元.女贞子等中药对小鼠触须毛囊体外培养生物学特征的研究.临床皮肤科杂志,2001,30(2): 81-84
62.彭光华,李忠,张声华.薄层色谱法分离鉴定枸杞子中的类胡萝卜素.营养学报,1998,20(1):76-78
63.甘璐,张声华.枸杞多糖的抗肿瘤活性和对免疫功能的影响.营养学报,2003,25(2):200-202
64.吕怀盛,张红梅,张波,等.枸杞多糖对 PG 细胞株增殖及凋亡的影响.宁夏医学院学报,2002,24(1):10-11,14
65.王静珍,熊建荣.枸杞多糖对小鼠胸腺和脾脏保护作用的研究.宁夏医学杂志,2001,23(11):661
66.齐春会,黄琳娟,张永祥,等.枸杞多糖合物及糖链的化学结构与免疫活性.中国药理学与毒理学杂志,2001,15(3):186-196
67.徐曼艳,王煜飞,张红峰,等.枸杞多糖对四氧嘧啶损伤离体大鼠胰岛细胞的作用.河北中医,2002,24(8):636-638
68.孙桂菊,张林,王少康,等.枸杞多糖、茶叶多糖混合物对Ⅱ型糖尿病大鼠降血糖作用及对糖尿病并发症相关指标的影响.食品研究与开发,2003,24(2):75-78
69.王德山,肖玉芳,董钢峰,等.枸杞实验性高血脂肝脂量效关系及毒性研究.实验研究,1997,24(12):567-568
70.施仁潮.枸杞子.杭州:浙江科学技术出版社,2002,12-22
71.李国莉,任彬彬,杨建军,等.枸杞多糖对小鼠耐力及体内抗氧化酶活性的影响.辽宁中医杂志,2002,29(10):634
72.邵邻相.佛手和枸杞提取物对小鼠皮肤胶原蛋白、SOD 含量及毛发生长的影响.中国中药杂志,2003,28(8):767-768
73.李贵新,张玲,王荟,等.G 淫羊藿苷诱导肿瘤细胞凋亡及其机制的研究.中国肿瘤生物治疗杂志,1997,4(3):235
74.赵勇,张玲,崔正言,等.淫羊藿苷对 IL-60 细胞诱导分化作用的研究.中国肿瘤杂志,1995,2(4):352
75.林新,李文魁,罗崇念,等.淫羊藿苷!对三种肿瘤细胞株增殖的抑制作用.中国药理学与毒理学杂志,1997,11(3):183
76.郭宝林,罗崇念,肖培根.淫羊藿多糖研究进展.中国中药杂志,1998,23(7):436
77.王敏,刘崇铭,张宝风.淫羊藿苷对血管平滑肌的作用.沈阳药学院学报,1993,10(3):185
78.赵勇,崔正言,张玲,等.淫羊藿苷协同诱生 IL-2、3、6 作用的研究.中国免疫学杂志,1996,12(1):43
79.孟宪丽,曾南,张艺,等.淫羊藿有效成分对老龄雄性大鼠下丘脑单胺类神经递质及其他脑功能作用的研究.中国中药杂志,1996,21(11):683
80.李祥,陈建伟,方泰惠,等.中国特有植物明党参化学成分和药理研究进展.中国野生植物资源,1998,17(2):13-16
1. 全国肿瘤防治研究办公室.中国试点市、县恶性肿瘤的发病与死亡.中国医药科技出版社,2000:25-26,32-33
2. 郁仁存,彭晓梅,饶爕卿,等.固本抑瘤 I 号配合化疗治疗恶性肿瘤临床与实验研究.中国中西医结合杂志,1997,14(7):392
3. 王笑民,郁仁存,饶爕卿,等.晚期非小细胞肺癌气虚血瘀证的研究.中国中西医结合杂志,1997,14(12):724
4. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
5. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.中国中医药信息杂志,2000,7(7):41-42
6. 张青,郁仁存,王禹堂,等.固本抑瘤 II 号对小鼠肺腺癌(L795)爪垫皮下移植后抑瘤作用及其术后生命延长率的试验研究. 中国中医药信息杂志,1997,4(01):14
7. Hannun JA. Apoptosis and dilemma of cancer chemotheraphy [J]. Blood, 1997, 89: 1845-1853
8. 崔艳君,陈若芸.鸡血藤化学和药理研究进展. 天然产物研究与开发,2001,14(4):72-78
9.汪伟民,汪波,刘荣玉,等.中药莪术油对小鼠 Lewis 肺癌抑制作用的实验研究.中国中医药科技,2003,10(6):353-354
1. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
2. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.国中医药信息杂志,2000,7(7):41-42
3. 饶燮卿,郁仁存,王笑民,等.益气活血法治疗中晚期胃癌的研究.中国中医药信息杂志,1998,5(2):44
4. 郁仁存,张青,王笑民,等.固本抑瘤 II 号结合化疗治疗肿瘤的临床研究.中医杂志,1999(增刊)
5. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
6. 韩锐.抗癌药物研究与实验技术[M].北京:北京医科大学中国协和医科大学联合出版社,1997,298
7. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1768
8 金正均.合并用药中的相加[J].中国药理学报,1980,1(1):70
9. 张志红,庄英枳,曹建国.甲基莲心碱增强顺氯氨铂对 Lewis 肺癌的化疗作用.肿瘤学杂志,2004,10(1):17-19
10.徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
11.谢冰芬,潘启超,刘宗潮,等.固本抑瘤 II 号方对抗癌药物的增效作用.癌症,1996,15(3):181-183
1. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
2. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.国中医药信息杂志,2000,7(7):41-42
3. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
4. 陈奇.中药药理研究方法学[M].北京:人民卫生出版社,1994,709-710
5. 孙卫民,王惠琴.细胞因子研究方法学[M].北京:人民卫生出版社,1999,65-66
6. 吕建新,金丽琴,陈国荣,等.细脚拟青霉对大鼠腹腔巨噬细胞的激活作用[J].中国免疫学杂志,1997,13(3):139-141
7. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1861
8. 刘汉丹,瞿佐发.黄芪的药理作用研究进展[J].现代中西医结合杂志,2002,11(18):1861
9. 李智军,魏连波,贺丰,等.黄芪多糖治疗大鼠系膜细胞增生性肾炎的实验研究[J].中国中西医结合肾病杂志,2000,1(4):206
10.秦叔逵,钱军,王琳.榄香烯治疗肺癌的临床观察与实验研究[J].中国肿瘤临床,1997,24(3):231-233
11.胡守友,陈龙帮,王靖华,等.β-榄香烯对小鼠黑色素瘤细胞的分化诱导作用[J].南京大学学报.自然科学版,1998,34(5):550-553
1. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
2. Migheli A, Cavalla P, Marino S, et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol, 1994, 53 (6): 606
3. Negoescu A, Lorimier P, Labat-Moleur. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem, 1996, 44 (9): 959
4. Wyllie AH, Kerr JFR, Currie AR. Apoptosis: cell death in tissue regμlation. J Pathol, 1987, 153 (4): 313
5. Wijsman JH, Jonker R, Keijzer R, et al. A new method to detect apopto sis in paraffin sections: in situ end-labeling of frag-mented DNA. J Histochem Cytochem, 1993, 41 (1): 7
6. Negoescu A, Lorimier P, Labat-Moleur. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem, 1996, 44 (9): 959
7. 杨骅,王仙平,郁琳琳,等.榄香烯抗癌作用与诱发肿瘤细胞凋亡[J].中华肿瘤杂志,1996,18(3):169
8. 徐学军,周子成,罗元辉,等.β-榄香烯诱导人肝癌细胞株 SMMC-7721 凋亡的研究[J].第三军医大学学报,1999,21(4):268-270
9. 吕怀盛,张红梅,张波,等.枸杞多糖对 PG 细胞株增殖及凋亡的影响[J].宁夏医学院学报,2002,24(1):10-11,14
2. 王英年,崔言刚,张春玲,等.P15 蛋白、血管内皮生长因子在肺癌组织中的表达及相关性研究.中华结核和呼吸杂志,2001,24(2):115
3. 王孝养,陈仕新,张珍祥,等.Survivin 基因在非小细胞肺癌中的表达及与P53、c-myc、k-ras 蛋白表达的关系.中华结核和呼吸杂志,2001,24(6):371-374
4. Vejda S, Posovszky C.Plasma from cancer patients festuring a charactristic protein composions mediates protein against apoptosis [J].Mol cell Proteomics. 2002, 1(5): 387-393
5. Zhan XQ, Guan YJ. Differential proteomic analysis of human lungadenocacinoma cell line A549 and normal cell line HEB[J].Sheng wu hua xue yu sheng wu wu li xue bao (shanghai), 2002, 34(1): 50-56
6. 危北海.循证医学与中医药学发展.中医药学信息,2003,20(5):123
7. Mattson KV, Abratt RP, Velde G. Doeetaxel as neoadjuvant therapy for radically treatable stage Ⅲ non-small-cell lung cancer: amμltinational radomised phase Ⅲ study. Acta Oncol, 2003, 14: 116-122
8. Garrido Lopez MP, Lago J, Gonzalez-Larriba L, et al. Neodjuvant chemotherapy with Gemcitabine (GEM), cisplath (CIS) and Docetaxel (DOC) in stage ⅢA N2 and T4N0 non-small-cell lung cancer (NSCLC) patients: spanish lung cancer group phase Ⅱ trial 9901. Proc Am Soc Clin Oncol, 2003, 22: 2620.
9. Antomio S, Rebecca P, Alberto T, et al. Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage ⅢA N2/ ⅢB nonsmall cell lung cancer (NSCLC): a mμlticenter phase Ⅱstudy with a 21 days schedμle: final resμlts. Proc Am Soc Clin Oncol, 2003, 22: 2669.
10.The international adjuvant lung cancer trial collaborative group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell-lung-cancer. New Engl J Med, 2004, 350(4): 351.
11.Winton T , Livingston R , Johnson D ,et al. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin ( CIS) in completely resected staged ⅠB and Ⅱ non-small cell lung cancer (NSCLC) interground JBR 10. Proc Am Soc Clin Oncol, 2004 , 23 (Suppl) : 7018a
12.吴一龙.非小细胞肺癌综合治疗的再认识.循证医学,2004,4(4):193-195
13.申文江,徐国镇,主编.放射肿瘤学新进展.北京:中国医药科技出版社,2001,289
14.王远东,赵健,刘健雄,等.射频治疗在局部晚期非小细胞肺癌综合治疗中的作用.中国肿瘤临床,2004,31(9):499-501
15.Raben D, Helf rich BA, Chan D, et al. ZD1839, as selective epidermal growth factor receptor tyrosine kinase inhibitor alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Seminn Oncol, 2002, 29 (s4): 37-46
16.Tsai CM, Chang KT, Wu L H, et al. Correlation between intrinsic chemoresistance and HER-2/ neμgene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res, 1996, 56: 206-209
17.Fukuoka M, Kris M, Giaccone G, et al. Phase Ⅱt rails of gefitinib (Iressa, ZD1839): rapid and durable objective responses in patients with advancednon-small-cell lung cancer (IDEAL1 and IDEAL2). Lung Cancer, 2003, 41 (Suppl 2): S247
18.Herbst RS. Dose-comparative monot herapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30 (1Suppl 1): 30-38
19.王树森,管忠霞,姜文奇,等.表皮生长因子受体酪氨酸激酶抑制剂 ZD1839对鼻咽癌细胞系的作用.癌症,2004,23(5):540-544
20.Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer togefitinib. New Engl J Med, 2004, 350(21): 2129-2139
21.Sandier AB. Clinical experience with tarceva. Lung Cancer. 2003, 41 (s3): s82
22.Miller VA, PatelJ, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patints with bronchioloaveolar cell carcinoma (BAC): preliminary resμlts of a phase II trial. Proc Am Soc Clin Oncol, 2003, 22: 619
23.Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer 2004, 6 (Suppl 1): S24-29
24.Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. New Engl J Med, 2004, 351 (4): 337-345
25.Kim ES. Cetuximab as a single agent or in combination with chemotherapy in lung cancer. Clin Lung Cancer, 2004, 6 (Suppl2): S80-84
26.Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2004, 23:618. Abs 7012
27.Mcarty MF, Wey J, Stoeltzing O, et al. ZD6474, a vascμlar endot helial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther, 2004, 3 (9): 1041-1048
28.Heymach JV, Dong RP, Dimery I, et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Resμlts of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol, 2004, 23: 207s, Abs 3051
29.Sandler AB, Gray R, Brahmer J, et al. A randomized phase III trial comparing bevacizumab/ carboplatin/ paclitaxel versus carboplatin/ paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2005, 23: 621s. Abs 7001
30.Wojtowicz-Praga SM, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol, 1998, 16: 2150-2156
31.Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastatafter response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol, 2002, 20: 4434- 4439
32.Rigas J R, Denham CA, Rinaldi D, et al. Adjuvant targeted therapy in unresectable lung cancer: The resμlts of two randomized placebo-controlled trials of BAY 12-9566, a Matrix Metalloproteinase Inhibitor (MMPI). Lung Cancer, 2003, 41(s2): s34
33.Gridelli C. How to combine cytotoxic and cytostatic agents. Lung Cancer, 2002, 38: s39-40
34.Nμgent FW, Graziano S, Collea R, et al. Docetaxel and COX-2 inhibitoion with celecoxib in progressive non-small cell lung cancer (NSCLC): promising progression-free survival in a Phase II study. Lung Cancer, 2003, 41 (s2): s35-s36
35.梅玫,余虹,张维铭,等.硫代修饰型反义寡核苷酸酶抑制肺癌细胞系端粒酶活性及增殖的研究.中华病理杂志,2000,29:204-207
36.Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a Bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol, 2002, 13 (4): 539-545
37.Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst, 2001, 93(6): 463-471
38.Kagawa S, Gu J, Swisher SG, et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53 resistant cancer lines. Cancer Res, 2000, 60 (5): 1157-1161
39.Jin Z, Dicker DT, Ei-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells sμggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 2002, 1 (1): 82-89
40.Huang X, Lin T, Gu J, et al. Combined TRAIL and Bax gene therapy prolongedsurvival in mice with ovarian cancer xenograft. Gene Ther, 2002, 9(20): 1379-1386
41.Ianniello GP, De Cataldis G, Comella P, et al. Visplatin, epirubicin and vindesine with or without lonidamine in the treatment of inoperable non-small cell lung carcinoma: a mμlticenter randomized trial. Cancer, 1996, 78 (1): 63-69
42.Paμl A, Bunn Jr MD, Ariel SMD, et al. New therapeutic strategies for lung cancer-biology and molecμlar biology come of age. Chest, 2000, 117 (4 Suppl 1): 163S-168S
43.Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer throμgh endobronchial injection. Chest, 2000, 118(4): 966-970
44.Schμler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: resμlts of a mμlticenter phase II study. J Clin Oncol, 2001, 19 (6): 1750-1758
45.Yuen A, Halsey J, Fisher GA ,et al. Phae I/ II trial of ISIS3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc Am Soc Clin Oncol, 2001, 20: 309. Abs 1234
46.Lynch TJ, Rayu R, Lind M, et al. Randomized phase Ⅲ trial of Ly90003 (ISIS3521) in patients with advanced NSCLC inital report. Proc Am Soc Clin Oncol, 2003, 22: 623. Abs2504
47.Boehm T , Folkmam J ,Browder T ,et al . Antiangiogenic therapy of experimental cancer does not induce acquired drμg resistance. Nature, 1997, 390 (6658): 404-407
48.Gatzemeier U, Rodriguez G, Treat J, et al. Triapazamine-cisplatin: the synergy. Br J Cancer, 1998, 77(Suppl 4): 415-417
49.Macaμlay VM ,O′Byrne KJ ,Saumders MP ,et al . Phase I study of int ropleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effeusions. Clin Cancer Res, 1999, 5 (3): 513-520
50.Liao F, Li Y, O’Connor W, et al. Monoclonal antibody to vascμlar endot helial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res, 2000, 60(24): 6805-6810
51.Zang Y, Griffith EC, Sage J, et al. Cell cycle inhibition by the antiangiogenic agent TNP-470 is mediated by p53 and p21 WAPF1/ CIP1. Proc Natl Acad Sci USA, 2000, 97 (12): 6427-6432
52.Hagedorm M, Bikfalvi A. Target molecμles for anti-angiogenic therapy: frombasic research to clinicle trials. Crit Rev Oncol Hematol, 2000, 34 (2): 89-110
53.Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med, 2000, 108 (6): 487-495
54.Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascμlar endot helial growth factor receptor into a remote organ. Cancer Res, 2000, 60 (8): 2169-2177
55.Li H, Lu H, Griscelli F, et al . Adenovirus-mediated delivery of a uPA/ uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther, 1998, 5(8): 1105-1113
56.Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg, 2002, 235 (4): 540-549
57.Zhou Y, McEarchern JA. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Cancer Immunol Immunother, 2003, 52 (7): 413-422
58.Ueda Y, Itoh T, Nukaya I, et al. Dendritic cell-based immunot herapy of cancer with carcinoembryonic antigen-derived, HLA-A24-rest ricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinoma. Int J Oncol, 2004, 24 (4): 909- 917
59.Butts C. A mμlticenter phase IIB randomized study of the liposomal muc1 vaccine L-BLP25 for immunot herapy of advanced non-small cell lung cancer (NSCLC). Proceedings from the 11th world conference on lung cancer, Barcelona, Spain, 2005, Abs O-083
60.Nemunaitis J, Sterman D. Granμlocyte-macrophage colony-stimμlating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst, 2004, 96 (4): 326- 331
61.Spira A, Ettinger DS. Mμltidisciplinary management of lung cancer. N Engl J Med, 2004, 350 (4): 379-392
62.Langer CJ. Role of targeted therapy in non-small cell lung cancer: hype or hope? Expert Rev Anticancer Ther, 2003, 3 (4): 443-455
63.朱熊兆.心理干预对人体免疫调节功能的影响.中国临床康复,2002,6(17):2520-2522
1. 王国智.肿瘤临床辨治体会.陕西中医,1997,18(4):191
2. 王云启.肺复方治疗非小细胶肺癌 30 例临床观察.湖南中医杂志,2000,16(3):9
3. 朱惠蓉.益肺抗癌饮治疗晚期肺癌 28 例临床观察.湖南中医杂志,2000,16(3):8
4. 魏华.晚期肺癌的中医药治疗.湖北中医杂志,2000,22(8):20
5. 王家辉.中药配合放化疗治疗晚期非小细胞肺癌 36 例.中国中西医结合杂志,1998,18(9):562
6. 孙维刚.孙宜麟治疗癌症临证举隅.辽宁中医杂志,1998,25(6):264
7. 张齐军.补肺汤在肺癌虚证中的应用.湖北中医杂志,1999,21(5):225
8. 韩新平.抗癌协定方加辨证用药治疗晚期肺癌 17 例观察.河北中医药学报,1999,14(2):13
9. 海青,李世业,付瑜,等.康莱特注射液治疗原发性肺癌的临床及病理学观察.中国肿瘤临床,1999,26(6):477-478
10.潘子民,人参皂甙 Rg3 对荷卵巢癌的严重免疫缺陷鼠的抗肿瘤血管生成作用的研究.中华妇科杂志,2002,37(4):227-230
11.计磊,陈士壮,李西启,等.晚期非小细胞肺癌中药治疗前后肿瘤细胞凋亡的对比观察.上海医药,1997,(11):30-31
12.陈孝银,沈卓群.琼玉膏对化疗实验肺癌小鼠 nm23 及 PCNA 基因蛋白表达的影响.安徽中医学院学报,2000,19(2):47-49
13.张青,郁仁存,丁瑞,等.固本抑瘤Ⅱ号对小鼠肺腺癌移植后抑瘤作用和术后存活率的实验研究.中国中医药信息杂志,1997,4(10):14-15
14.韩明权,刘嘉湘,高虹,等.24 味中药对人肺腺癌细胞核酸和蛋白质及细胞周期的影响观察.中国中西医结合杂志,1995,15(3):147-149
15.许玲.刘嘉湘教授辨治肺癌经验.中医药信息,1995,12(4):36
16.唐文秀,张宗歧,林红生,等.中医药治疗晚期原发性非小细胞肺癌的临床观察.中医杂志,1994,35(5):283
17.范忠泽,孙钰,袁秀英.中医药对晚期原发性肺腺癌的疗效观察.中国中西医结合杂志,1994,14(9):561
18.王笑民,郁仁存,王禹堂,等.晚期非小细胞肺癌患者气虚血瘀证的研究.中国中西医结合杂志,1994,14(12):724
19.周晓园.顾报东治疗肿瘤的经验.山东中医杂志,1999,21(5):225
20.王云启.肺复方治疗非小细胞肺癌 30 例临床观察.湖南中医杂志.2000,16(3):9
21.张齐军.补肺汤在肺癌虚证中的应用.湖北中医杂志,1999,21(5):225
22.王敬亭.中西医结合治疗晚期肺癌 14 例.中国中西医结合杂志.1997,17(1):56
23.王永林,苏旭春.扶正清肺方减轻肺癌化疗反应的临床研究.中药药理与临床,2000,16(5):45
24.韩建国,魏兰波.益气养阴汤治疗晚期非小细胞肺癌的临床观察.辽宁中医杂志,2003,30(2):123
25.黄兆明.中药加化疗治疗晚期非小细胞肺癌疗效分折.中国中西医结合杂志,1997,17(1):26
26.王笑民.益气活血散结法配合化疗治疗晚期非小细胞肺癌的研究.中国中西医结合杂志.1997,17(2):86
27.王晓.中西医结合治疗晚期非小细胞肺癌疗效观察.中国中西医结合杂志,1997,17(2):13
28.潘淑云,孙维刚,丁隽英.中药软坚散结汤治疗晚期非小细胞肺癌 30 例.辽宁中医杂志,2002,29(12):723
29.陈世伟.温阳益气汤治疗晚期肺癌 50 例临床观察.山东中医杂志,2002,20(10):589
30.刘加宽.六仙汤治疗晚期非小细胞性肺癌临床观察.中国中西医结合杂志,2001,21(1):57
31.付显成.益气活血方配合放疗及介入化疗治疗晚期非小细胞肺癌的临床研究[J].中国中西医结合外科杂志,2000,6(5):313
32.刘秀芳.中药配合同步放、化疗对晚期非小细胞肺癌影响.中国中西医结合杂志,2000,20(6):427
33.郭孝忠,宋翠力,张存悌.肺癌用药规律初探.辽宁中医杂志,2002,29(5):273
34.宣丽华,徐福,刘鲁明.温经膏穴位外敷治疗肺癌疗效观察.浙江中西医结合杂志,2000,10(10):596～597
35.田建辉,刘运霞,祝宝刚,等.抗癌腹水膏穴位贴敷对艾氏腹水癌小鼠外周血 sIL-2R 水平的影响.中国针灸,2001,21(9):559～561
36.杨葆康,姜仁成.灵仙丹治疗中晚期肺癌 16 例.辽宁中医杂志,1994,21(7):323
37.谢止中,刘丹,沈汉澄.孔最穴位注射止血敏治疗中、晚期肺癌出血 53 例.中国中西医结合杂志,1998,18(8):495
1. 全国肿瘤防治研究办公室,中国试点市、县恶性肿瘤的发病与死亡.中国医药科技出版社,2000:25-26,32-33
2. 张青,郁仁存,王笑民,等.固本抑瘤Ⅱ号结合化疗治疗肿瘤的临床研究.中医杂志,1999(增刊)
3. 张青,郁仁存,王笑民,等.固本抑瘤Ⅱ号抗肿瘤的临床研究.中国中医药信息杂志,2000,7(7):41-42
4. 谢冰芬,潘启超,刘宗潮,等.固本抑瘤 II 号方对抗癌药物的增效作用.癌症,1996,15(3):181-183
5. 张青,郁仁存,丁瑞,等.固本抑瘤 II 号对小鼠肺腺癌移植后抑瘤作用和术后存活率的实验研究.中国中医药信息杂志,1997,4(10):14-15
6. 田宏印.黄芪化学研究及其有效成分[J] .云南民族学院报(自然科学版),1996,45(1):75-76
7. 马占好,张春艳,刘旭,等.黄芪多糖对小鼠体内六种细胞系瘤株抑瘤作用的实验研究[J] .中医药学报,1996,(4): 551
8. 郭颖杰.黄芪水煎液对人黑色素瘤细胞的杀伤作用.中草药, 2001,(31):114
9. 王涌,胡志前,成志刚,等.中药黄芪对阻塞性黄疸大鼠细胞免疫功能的影响[J] .肝胆外科杂志,2000,8(1):64-66
10.张建新.黄芪对小鼠免疫功能影响的研究.时珍国医国药,2000,11(6)∶488
11.洪介民,邱健行,胡祖光.黄芪多糖在体外对小鼠粒巨噬系祖细胞的影响.中医药学报,1997,(6):441
12.李智军,魏连波,贺丰,等.黄芪多糖治疗大鼠系膜细胞增生性肾炎的实验研究.中国中西医结合肾病杂志,2000,1(4):206
13.焦柏忠,刘晓晶,吕美丽,等.肝脾康胶囊药理作用研究.中草药,1999,30 (12):926-929
14.马红.黄芪抑制大鼠肝星状细胞增殖及胶原分泌的研究.中国中医药信息杂志,2001,8(4):35
15.周钦.芪对肾小球疾病物质代谢紊乱的调节作用.中草药,1999,30(5):386
16.周吉燕.黄芪中不同提取成分对在体大鼠心肌缺血-再灌注损伤的心功能影响.中国中药杂志,2000,25(5):300
17.冯国清.黄芪对大鼠心肌缺血-再灌注损伤的防护作用.中药药理与临床,1997,13(3):27
18.梁明,韩竹梅,梁小光,等.黄芪冻干粉对大鼠离体心脏的作用.中草药,2000,31(11):846-847
19.石瑞如,何路明,胡雅儿,等.黄芪对老年大鼠脑 M 胆碱受体的调节作用.中医杂志,1998,(11):685
20.金若敏,张晓晨,陈长勋,等.黄芪毛状根药理作用的研究.中国中药杂志,1999,24(10):619-621
21.马占好,张春艳,刘旭,等.黄芪多糖对小鼠体内六种细胞系瘤株抑瘤作用的实验研究.中医药学报,1996,(4):55
22.洪庚辛.黄芪水提物的促智作用.中国中药杂志,1994,19(11):687
23..胡守友,陈龙帮,王靖华,等.β-榄香烯对小鼠黑色素瘤细胞的分化诱导作用.南京大学学报.自然科学版,1998,34(5):550-553
24.高宪琴,王永才,苗小艳,等.榄香烯抗白血病作用的临床观察.大连医科大学学报,1999,21(1):27-28
25.石灵春,吴万根,张维彬,等.莪术油对小鼠肝癌增殖细胞核抗原的影响.世界华人消化杂志,1999,7(2):156-157
26.杨骅,王仙平,郁琳琳,等.榄香烯抗癌作用与诱发肿瘤细胞凋亡.中华肿瘤杂志,1996,18(3):169
27.徐学军,周子成,罗元辉,等.β-榄香烯诱导人肝癌细胞株 SMMC-7721 凋亡的研究.第三军医大学学报,1999,21(4):268-270
28.吴万垠,罗云坚,程剑华,等.莪术油对小鼠肝癌细胞 DNA 作用的图像分析.中西医结合肝病杂志,1999,9(1):18
29.崔秀云,李德山.β-榄香烯对 RNA 聚合酶活性的抑制及与 DNA 的结合.中国药理学报,1991,7(3):228
30.李应东,李啸红,王毓美,等.莪术对硫酸镍诱导的人外周血淋巴细胞非程序脱氧核糖核酸合成的影响.中国中西医结合杂志,1994,14(11):647-650
31.陈剑群,吴克俭,费素娟.榄香烯乳注射液治疗中晚期消化系肿瘤前后 T 淋巴细胞亚群的动态观察.中国肿瘤临床,1996,23(4):299-301
32.齐永长,吴厚生,胡新美,等.β-榄香烯、丝裂霉素 C 及热休克对小鼠 H22肝癌细胞 HSP70 表达的影响.上海免疫学杂志,1998,18(5):280-282
33.卞长武,王东荣,郭文来,等.莪术对小白鼠免疫功能的影响.中国中医药信息杂志,1997,4(2):29
34.李振波,丘和明,刘国普,等.清毒饮和养正片对环磷酰胺所致的造血抑制小鼠粒系造血的影响.广州中医药大学学报,1999,16(1):34-37
35..薄芯,杜明莹,戌梅.沙参、砂仁、猪苓、莪术和鸡血藤对环磷酰胺毒副反应影响的实验研究.中国中医药科技,1997,4(3):153,154,175
36.茅国新,高志兰,翟明之.榄香烯治疗晚期非小细胞肺癌的研究.中国肿瘤临床,1996,23(1):73-75
37.毛春芹,谢辉,陆免林.莪术炮制品的抗血小板聚集及抗凝血作用.中药材,2003,23(7):212-213
38.申庆亮.莪红注射液对血液流变学影响.中草药,1992,23(6):305-307
39.陈梅芳,丁钰熊,王家冲,等.大白鼠 5/6 肾切除所致慢性肾衰动物模型的中药疗效观察.中国医药学报,1988,3(6):24-27
40.杜兰屏,胡仲仪,邓跃毅,等.莪术对肾脏细胞外基质影响的实验研究.上海中医药杂志,2002,6(1):38-39
41.李应东,李啸红,王毓变.中药莪术抗致突变作用的初步研究.中国优生与遗传杂志,1999,7(1):22-23
42.李莲姬,韩春姬,崔山田,等.莪术对老年小鼠学习记忆与脂质过氧化作用的影响.中药材,1998,21(10):522-523
43.王鑫,刘玉瑛,史天良,等.白术挥发油抗实体瘤的作用研究.中国药物与临床,2002,2(4):239
44.焦新生,刘朝奇,朝莉,等.黄芪和白术对感染的色念珠菌的荷瘤鼠作用的实验.上海免疫学杂志,1995,15(5):313
45.关晓辉,曲娴,杨志萍,等.白术挥发油对小鼠免疫功能的影响.北华大学学报(自然科学版),2001,2(2):122
46.周德文.术类的药理和药效.国外医药·植物药分册,1996,11(3):120-122
47.余上才,章育正,赵慧娟,等.枸杞子和白术免疫调节作用的实验研究.上海免疫学杂志,1994,14(1):12
48.吕圭源.白术抗衰老作用研究.现代应用药学,1996,13(5):26-29
49.马晓松,樊雪萍,陈忠.白术对离体豚鼠回肠收缩的影响.新消化病学杂志,1996,4(11):603
50..蒲含林,王正濂,黄巧娟,等.双白术内酯对豚鼠离体心房肌的作用.中国药理学通报,2000,16(1):60
51.李继承,吕志莲,石光和.腹膜孔的药物调节和计算机图象处理.中国医学科学院学报,1996,18(3):219
52.陈道峰.中药鸡血藤的原植物调查与商品鉴定.中草药,1993,24(1):34
53.崔艳君,陈若芸.鸡血藤化学和药理研究进展.天然产物研究与开发,2002,14(4):72-78
54.李静.鸡血藤化学成分的研究Ⅱ.中国药学杂志,1999,34(10):686
55.Xiu Wei Yang et al. Anti-lipid peroxidative effect of an extract of the stems of Kadsura heteroclita and its major constituents, kadsurin, in mice. Chen. Ppharm. Bμll, 1992, 40(2): 406
56.程小芳,何明芳,张颖,等.女贞子化学成分的研究.中国药科大学学报,2000,31(3):170
57.孟静岩,片岗宽章,保岛一树,等.女贞子苋芪汤抗癌转移的离体实验研究.天津中医学院学报,2001,20(3):32-34
58.丁安伟,孟丽.女贞子多糖的免疫调节作用研究.中药药理与临床,2001,17 (2):11-12
59.王昊,闰小萍.通脉益智胶囊对 30 例血管性痴呆患者内皮素和降钙素基因相关肽的影响.北京中医药大学学报,2000,23(2):64-65
60.彭小英,李晴宇,侯芳,等.复方女贞子降血糖作用的实验研究.上海实验动物科学,2001,21(2):103-104
61.范卫星,朱文元.女贞子等中药对小鼠触须毛囊体外培养生物学特征的研究.临床皮肤科杂志,2001,30(2): 81-84
62.彭光华,李忠,张声华.薄层色谱法分离鉴定枸杞子中的类胡萝卜素.营养学报,1998,20(1):76-78
63.甘璐,张声华.枸杞多糖的抗肿瘤活性和对免疫功能的影响.营养学报,2003,25(2):200-202
64.吕怀盛,张红梅,张波,等.枸杞多糖对 PG 细胞株增殖及凋亡的影响.宁夏医学院学报,2002,24(1):10-11,14
65.王静珍,熊建荣.枸杞多糖对小鼠胸腺和脾脏保护作用的研究.宁夏医学杂志,2001,23(11):661
66.齐春会,黄琳娟,张永祥,等.枸杞多糖合物及糖链的化学结构与免疫活性.中国药理学与毒理学杂志,2001,15(3):186-196
67.徐曼艳,王煜飞,张红峰,等.枸杞多糖对四氧嘧啶损伤离体大鼠胰岛细胞的作用.河北中医,2002,24(8):636-638
68.孙桂菊,张林,王少康,等.枸杞多糖、茶叶多糖混合物对Ⅱ型糖尿病大鼠降血糖作用及对糖尿病并发症相关指标的影响.食品研究与开发,2003,24(2):75-78
69.王德山,肖玉芳,董钢峰,等.枸杞实验性高血脂肝脂量效关系及毒性研究.实验研究,1997,24(12):567-568
70.施仁潮.枸杞子.杭州:浙江科学技术出版社,2002,12-22
71.李国莉,任彬彬,杨建军,等.枸杞多糖对小鼠耐力及体内抗氧化酶活性的影响.辽宁中医杂志,2002,29(10):634
72.邵邻相.佛手和枸杞提取物对小鼠皮肤胶原蛋白、SOD 含量及毛发生长的影响.中国中药杂志,2003,28(8):767-768
73.李贵新,张玲,王荟,等.G 淫羊藿苷诱导肿瘤细胞凋亡及其机制的研究.中国肿瘤生物治疗杂志,1997,4(3):235
74.赵勇,张玲,崔正言,等.淫羊藿苷对 IL-60 细胞诱导分化作用的研究.中国肿瘤杂志,1995,2(4):352
75.林新,李文魁,罗崇念,等.淫羊藿苷!对三种肿瘤细胞株增殖的抑制作用.中国药理学与毒理学杂志,1997,11(3):183
76.郭宝林,罗崇念,肖培根.淫羊藿多糖研究进展.中国中药杂志,1998,23(7):436
77.王敏,刘崇铭,张宝风.淫羊藿苷对血管平滑肌的作用.沈阳药学院学报,1993,10(3):185
78.赵勇,崔正言,张玲,等.淫羊藿苷协同诱生 IL-2、3、6 作用的研究.中国免疫学杂志,1996,12(1):43
79.孟宪丽,曾南,张艺,等.淫羊藿有效成分对老龄雄性大鼠下丘脑单胺类神经递质及其他脑功能作用的研究.中国中药杂志,1996,21(11):683
80.李祥,陈建伟,方泰惠,等.中国特有植物明党参化学成分和药理研究进展.中国野生植物资源,1998,17(2):13-16
1. 全国肿瘤防治研究办公室.中国试点市、县恶性肿瘤的发病与死亡.中国医药科技出版社,2000:25-26,32-33
2. 郁仁存,彭晓梅,饶爕卿,等.固本抑瘤 I 号配合化疗治疗恶性肿瘤临床与实验研究.中国中西医结合杂志,1997,14(7):392
3. 王笑民,郁仁存,饶爕卿,等.晚期非小细胞肺癌气虚血瘀证的研究.中国中西医结合杂志,1997,14(12):724
4. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
5. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.中国中医药信息杂志,2000,7(7):41-42
6. 张青,郁仁存,王禹堂,等.固本抑瘤 II 号对小鼠肺腺癌(L795)爪垫皮下移植后抑瘤作用及其术后生命延长率的试验研究. 中国中医药信息杂志,1997,4(01):14
7. Hannun JA. Apoptosis and dilemma of cancer chemotheraphy [J]. Blood, 1997, 89: 1845-1853
8. 崔艳君,陈若芸.鸡血藤化学和药理研究进展. 天然产物研究与开发,2001,14(4):72-78
9.汪伟民,汪波,刘荣玉,等.中药莪术油对小鼠 Lewis 肺癌抑制作用的实验研究.中国中医药科技,2003,10(6):353-354
1. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
2. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.国中医药信息杂志,2000,7(7):41-42
3. 饶燮卿,郁仁存,王笑民,等.益气活血法治疗中晚期胃癌的研究.中国中医药信息杂志,1998,5(2):44
4. 郁仁存,张青,王笑民,等.固本抑瘤 II 号结合化疗治疗肿瘤的临床研究.中医杂志,1999(增刊)
5. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
6. 韩锐.抗癌药物研究与实验技术[M].北京:北京医科大学中国协和医科大学联合出版社,1997,298
7. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1768
8 金正均.合并用药中的相加[J].中国药理学报,1980,1(1):70
9. 张志红,庄英枳,曹建国.甲基莲心碱增强顺氯氨铂对 Lewis 肺癌的化疗作用.肿瘤学杂志,2004,10(1):17-19
10.徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
11.谢冰芬,潘启超,刘宗潮,等.固本抑瘤 II 号方对抗癌药物的增效作用.癌症,1996,15(3):181-183
1. 唐武军,王笑民,郁仁存,等.固本抑瘤 II 号联合 MVP 方案治疗晚期 NSCLC.中国中医药信息杂志,2001,8(7):43-44
2. 张青,郁仁存,唐武军,等.固本抑瘤 II 号抗肿瘤的临床研究.国中医药信息杂志,2000,7(7):41-42
3. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
4. 陈奇.中药药理研究方法学[M].北京:人民卫生出版社,1994,709-710
5. 孙卫民,王惠琴.细胞因子研究方法学[M].北京:人民卫生出版社,1999,65-66
6. 吕建新,金丽琴,陈国荣,等.细脚拟青霉对大鼠腹腔巨噬细胞的激活作用[J].中国免疫学杂志,1997,13(3):139-141
7. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1861
8. 刘汉丹,瞿佐发.黄芪的药理作用研究进展[J].现代中西医结合杂志,2002,11(18):1861
9. 李智军,魏连波,贺丰,等.黄芪多糖治疗大鼠系膜细胞增生性肾炎的实验研究[J].中国中西医结合肾病杂志,2000,1(4):206
10.秦叔逵,钱军,王琳.榄香烯治疗肺癌的临床观察与实验研究[J].中国肿瘤临床,1997,24(3):231-233
11.胡守友,陈龙帮,王靖华,等.β-榄香烯对小鼠黑色素瘤细胞的分化诱导作用[J].南京大学学报.自然科学版,1998,34(5):550-553
1. 徐淑云,卞如濂,陈修.药理实验方法学[M].第 3 版.北京:人民卫生出版社,2002,1770
2. Migheli A, Cavalla P, Marino S, et al. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol, 1994, 53 (6): 606
3. Negoescu A, Lorimier P, Labat-Moleur. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem, 1996, 44 (9): 959
4. Wyllie AH, Kerr JFR, Currie AR. Apoptosis: cell death in tissue regμlation. J Pathol, 1987, 153 (4): 313
5. Wijsman JH, Jonker R, Keijzer R, et al. A new method to detect apopto sis in paraffin sections: in situ end-labeling of frag-mented DNA. J Histochem Cytochem, 1993, 41 (1): 7
6. Negoescu A, Lorimier P, Labat-Moleur. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem, 1996, 44 (9): 959
7. 杨骅,王仙平,郁琳琳,等.榄香烯抗癌作用与诱发肿瘤细胞凋亡[J].中华肿瘤杂志,1996,18(3):169
8. 徐学军,周子成,罗元辉,等.β-榄香烯诱导人肝癌细胞株 SMMC-7721 凋亡的研究[J].第三军医大学学报,1999,21(4):268-270
9. 吕怀盛,张红梅,张波,等.枸杞多糖对 PG 细胞株增殖及凋亡的影响[J].宁夏医学院学报,2002,24(1):10-11,14